Avalo Therapeutics appoints Michael Heffernan as Chairman, separating roles from CEO Garry Neil

Avalo Therapeutics, Inc.

Michael Heffernan appointed Chairman of the Board, effective March 25, 2025; succeeds Dr. Garry Neil who remains CEO and Board member.
Heffernan brings experience building biopharma companies and executing exits; will guide pipeline including AVTX-009 in Phase 2 LOTUS trial for HS.
Company states sufficient capital to achieve potentially transformative data readout from LOTUS trial next year.
Board also approved Amended and Restated Non-Employee Director Compensation Plan to attract and retain qualified directors.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Heffernan

Chairman of the Board

AVTX · Avalo Therapeutics, Inc.

Effective: 2025-03-25
Filed: March 26, 2025, 7:59 PM ET

On March 25, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Michael Heffernan to the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Heffernan was appointed as Chairman of the Board at Avalo Therapeutics, Inc..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

On March 25, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Michael Heffernan to the Board, effective immediately.

View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-014833

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.